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EDITORIAL




o explain the atherogenicity and the antiatheroge-
nicity of LDLs (low-density lipoproteins) and HDLs 
(high-density lipoproteins), respectively, many stu-
dents and patients are taught that LDLs deliver choles-
terol from liver to peripheral cells, whereas HDLs return 
excess cholesterol from peripheral cells back to liver for 
biliary excretion by reverse cholesterol transport (RCT). 
This keep-it-simple scheme is misleading. First, the vast 
majority of LDL cholesterol is taken up by the liver rather 
than by nonhepatic peripheral cells. Most of the latter 
can synthesize enough cholesterol for their need and 
limit the uptake of cholesterol with LDL by downregu-
lation of LDLR (LDL receptor) expression. Only cells 
expressing nonsterol regulated scavenger receptors, 
notably macrophages, for example, in the atherosclerotic 
plaque, can take up excessive amounts of cholesterol 
via modified LDL.1 Second, a large proportion of choles-
terol carried by LDL is derived from HDL. The exchange 
of triglycerides carried by VLDLs (very-low-density lipo-
proteins) and their remnants against cholesteryl esters 
carried by HDL through the action of CETP (choles-
teryl ester transfer protein) is an important source of 
LDL cholesterol. By CETP-mediated receipt of choles-
teryl esters from HDL for subsequent LDLR-mediated 
uptake into the liver, LDL contributes to RCT. The block-
age of this pathway may be one reason for the futility of 
CETP inhibitors toward prevention of major cardiovas-
cular events, especially when combined with statins that 
upregulate LDLR and thereby enhance hepatic removal 
of LDL cholesterol.2
Article, see p 778
In the current issue of Circulation Research, Cedo et al3 
highlight the importance of an additional and less well-
known mechanism, by which LDL and the LDLR path-
way contribute to RCT, namely by enhancing the flux of 
unesterified cholesterol (UC) from macrophages to the 
liver for fecal excretion. By cell culture experiments, they 
reproduced the findings of several laboratories that the 
presence of LDL increases the ability of plasma, native 
and reconstituted HDL, apoA-I, or albumin to promote 
efflux of UC from fibroblasts or different macrophage 
cell lines.4–6 Cedo et al extend this previous knowledge 
by investigating the role of ABCA1 (ATP binding cas-
sette transporter A1) and ABCG1 (ATP binding casette 
transporter G1). They report that LDL enhances efflux 
of UC directly with the help of ABCG1 and indirectly by 
serving as a sink for UC initially released from cells by 
HDL or lipid-free apoA-I through ABCG1 or ABCA13.
Their experiments like the previous studies4–6 found that 
HDL shuttles UC very rapidly to LDL. The relative con-
centrations of HDL and LDL define the capacity of LDL 
to serve as an acceptor of cellular UC. The lower the 
concentration of HDL or the higher the concentration of 
LDL in the cell culture medium, the more cell-derived UC 
occurs in LDL. ApoB (apolipoprotein B)-containing lipo-
proteins were found to contribute about 40% to the cho-
lesterol efflux capacity (CEC) of normolipidemic plasma 
but 65% to 85% to the CEC of plasmas from patients 
with HDL deficiency.7 In the present study, plasmas of 
patients with familial hypercholesterolemia and plasmas 
of HAPOB Tg (transgenic for human ApoB) mice con-
tained larger proportions of cell-derived UC in LDL than 
control plasmas from normolipidemic subjects and wild-
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CEC for plasmas of HAPOB Tg mice.3 Conversely, LDL 
apheresis decreases CEC of total plasma.8 Interestingly 
and in contrast to LDL, VLDL does not support HDL in 
promoting cholesterol efflux from cells. Rather by con-
trast, VLDL inhibited HDL-induced cholesterol efflux, 
possibly by sterical hindrance of HDL/ABC transporter 
interaction.3 An alternative explanation may be the 
recently demonstrated role of VLDL as a donor of UC 
to HDL.9 Possibly, the UC transfer from VLDL to HDL 
competes with the UC transfer from cells to HDL.
LDL is not a permanent sink of cell-derived UC but 
distributes and traffics it for further metabolism. Cell-
derived UC rapidly accumulating in LDL is slowly redis-
tributed to HDL for esterification by lecithin:cholesterol 
acyltransferase.4 Removal of LDL impairs the activity 
of plasma to esterify cell-derived UC.4 Cedo et al3 now 
show in mice that LDL and LDLR limit the reverse trans-
port of radioactive UC from macrophages, installed either 
in the peritoneum or in the skin, to the feces. Knockout of 
Ldlr and enhanced LDLR degradation by overexpression 
of PCSK9 (proprotein convertase subtilisin/kexin type 9) 
led to both the accumulation of macrophage-derived UC 
in LDL and decreased excretion of macrophage-derived 
UC with the feces.3 These findings generally support 
the hypothesis that LDL and LDLR are important con-
tributors to RCT, even in the absence of CETP, which is 
not expressed in mice.2,10 However, the livers of neither 
Ldlr−/− mice nor Ldlr−/−*HAPOB Tg mice nor mice overex-
pressing PCSK9 contained less radioactive cholesterol 
as compared with wild-type control mice. These data 
do not contradict the general conclusion that LDL and 
LDLR limit RCT in mice but raise the question on alterna-
tive pathways for fecal cholesterol excretion, for example, 
transintestinal cholesterol excretion, which also involves 
LDL and is inhibited by PCSK9.11
The murine in vitro and in vivo models raise ques-
tions on the applicability of the data to humans.10 For 
example, SR-BI (scavenger receptor BI) makes a larger 
contribution to cholesterol efflux from human macro-
phages than from murine macrophages.12 As the con-
sequence of CETP deficiency, selective uptake of HDL 
cholesterol through SR-BI is the major route of conclud-
ing RCT in mice.10 In humans, CETP-mediated transfer 
of cholesteryl esters from HDL to LDL and subsequent 
LDLR-mediated LDL uptake eliminates at least half of 
HDL cholesterol from the circulation.10 Although the UC 
transfer from HDL to LDL does not involve CETP, the 
predominance of the LDLR pathway in humans suggests 
that the findings in mice may underestimate its impor-
tance for RCT in humans. Conversely, the relevance of 
transintestinal cholesterol excretion for human choles-
terol homeostasis is little understood.11
With respect to atherosclerosis, it is important to note 
that cholesterol efflux from macrophage foam cells hap-
pens in the arterial intima rather than in the plasma of the 
blood stream. According to our nowadays understanding 
of atherosclerosis, LDL does not leave the arterial wall 
but is retained in the extracellular matrix of the arterial 
intima by binding to proteoglycans, modified, and taken 
up by macrophages.1 By contrast, HDL that has entered 
the arterial wall and eventually been loaded with mac-
rophage-derived cholesterol can leave the arterial wall, 
probably via lymphatics.13 Within the LDL sequestering 
environment of the arterial wall, the rapid transfer of UC 
from HDL to LDL may hence rather promote the accu-
mulation of extracellular cholesterol rather than acceler-
ate RCT. However, the transfer of both unesterified and 
esterified cholesterol from HDL to LDL for RCT may 
have occurred in evolution to relieve potentially danger-
ous situations of cellular cholesterol overload other than 
atherosclerosis, for example, caused by the clearance of 
cells in the reticulohistiocytic system or lipolysis in adi-
pose tissue during prolonged fasting.
Many clinical and epidemiological studies measured 
CEC of ApoB-depleted serum or plasma as surrogates of 
HDL functionality and found it associated with the presence 
or incidence of atherosclerotic cardiovascular disease.12,14 
However, despite increasing CEC, CETP inhibitors did not 
reduce major cardiovascular event rates in randomized 
controlled trials.2,12 The strong impact of LDL on CEC of 
plasma raises the question whether the use of total rather 
than ApoB-depleted serum or plasma improves the predic-
tive value of CEC. Only one study compared the 2 speci-
mens toward their prognostic performance. In this study,15 
CEC of total serum but not CEC of ApoB-depleted serum 
was associated with all-cause mortality independently of 
HDL cholesterol and other risk factors.
In conclusion, by using state-of-the-art experimental 
models, Cedo et al3 confirm that LDL amplifies the cho-
lesterol efflux mediated by HDL. They extend previous 
knowledge by unraveling the contribution of ABCA1 
and ABCG1 and by showing the in vivo relevance of 
LDL and LDLR for RCT of macrophage-derived cho-
lesterol. The relevance of these findings for human 
(patho)physiology, especially atherosclerosis, needs to 
be shown. However, they should have impact on the 
design of assays to determine CEC.
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